Nagi Bioscience at Startup Pitch ARDD2025

Value of the Information & Strength of the Argument

The value of the information lies in the presentation of a novel technological platform for aging research, with specific data on lifespan and healthspan improvements from metformin and rapamycin. The argumentation is solid, as the founder provides concrete examples and explains the advantages of their automated system over traditional methods. However, the presentation is a commercial pitch, so the claims are not independently verified and may be biased. The Q&A section adds credibility by addressing technical questions about the technology and business model.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate: the founder references known molecules like metformin and rapamycin, and mentions that C. elegans has been used to develop drugs on the market, but no specific studies are cited. The sources are not detailed, and the presentation is primarily based on the company’s own data. The title accurately reflects the content, as it is a startup pitch. The description provides minimal context, but the video is part of a conference, which adds some credibility.

The title accurately reflects the content: a startup pitch at an aging research conference.

7/10

Presentation by a company founder with specific technical details and data, but limited independent verification and potential commercial bias.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and problem statement: bottleneck in validating anti-aging interventions.
• 01:00Presentation of Nagi's solution: all-in-one platform with C. elegans, automation, and AI.
• 02:00Examples of lifespan data with metformin and rapamycin.
• 03:00Introduction of NagiAge aging clock and healthspan biomarkers.
• 04:00Data on metformin improving healthspan and specific biomarkers.
• 05:00Company overview: founded 2019, EPFL spin-off, 27 FTEs, 25+ customers.
• 06:00Q&A: business model, cost, and market size.
• 07:00Q&A: microfluidic technology and comparison with traditional methods.
• 08:00Q&A: future funding plans and focus on commercial activities.

• Nagi Bioscience website — Company website for more information on the platform.

• Nagi Bioscience website — Official company information supporting the claims.